Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.

摘要: Backgroud SPARC-like protein 1 (SPARCL1), a member of extracelluar matrix glycoprotein, is involved in many physiological functions. Methods Tissue microarray (TMA) blocks were constructed based on 1,072 Chinese patients, containing both gastric cancer (GC) tissues and adjacent normal mucosa tissues. We analyzed the expression SPARCL1 from mRNA level, using Real-time quantitative polymerase chain reaction (qRT-PCR), semi-quantitative PCR, immunohistochemistry (IHC), Western blotting. Loss heterozygosity analysis at gene locus was carried out ten paired tumor matched tissues. Results SPARCL1 significantly reduced specimens compared with Down-regulation detected 413 cases (38.7%) primary Kaplan–Meier survival curves demonstrated that SPARCL1-positive patients had better median time than SPARCL1-negative (59 months vs. 28 months, P = 0.001). Multivariate revealed an independent prognostic factor adenocarcinoma no metastasis well/moderately differentiated. The incidence LOH for each individual marker 12.5% (1/8) D4S2462, 20% (2/10) D4S2929, 33.3% (3/9) SPARCL1. Conclusions Our study clinical significance expression, providing basis loss negative event GC progression prognosis. Furthermore, might be considered to potential differentiation marker. J. Surg. Oncol. 2012; 105:31–37. © 2011 Wiley Periodicals, Inc.